Louisiana State Employees Retirement System Buys New Stake in ADMA Biologics Inc $ADMA

Louisiana State Employees Retirement System purchased a new stake in ADMA Biologics Inc (NASDAQ:ADMA) during the first quarter, HoldingsChannel.com reports. The fund purchased 105,500 shares of the biotechnology company’s stock, valued at approximately $951,000.

A number of other institutional investors also recently bought and sold shares of ADMA. Summit Securities Group LLC acquired a new position in shares of ADMA Biologics during the 4th quarter worth about $29,000. Optima Capital LLC acquired a new stake in shares of ADMA Biologics during the 4th quarter worth about $36,000. iSAM Funds UK Ltd purchased a new stake in ADMA Biologics during the third quarter worth approximately $34,000. RiverPark Advisors LLC purchased a new stake in ADMA Biologics during the third quarter worth approximately $35,000. Finally, Morse Asset Management Inc acquired a new position in ADMA Biologics in the fourth quarter valued at approximately $44,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

Key ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Neutral Sentiment: Multiple law firms, including Rosen, Bronstein, Schall, Glancy Prongay, Berger Montague, KSF, Faruqi & Faruqi, and Kirby McInerney, issued reminders about the ongoing ADMA Biologics securities class action and the approaching August 10 lead plaintiff deadline. Article: Rosen, National Investor Counsel, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ADMA
• Neutral Sentiment: The complaints allege violations of federal securities laws and claim investors who bought ADMA shares during the class period may have suffered losses, which keeps legal risk in focus. Article: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
• Neutral Sentiment: One filing specifically alleges ADMA made misrepresentations about its revenue sources, adding to concerns about the company’s prior disclosures. Article: ADMA Shareholder News: ADMA Biologics Accused of Making Misrepresentations about its Revenue Sources in Securities Fraud Class Action

Analyst Ratings Changes

Several equities analysts have commented on the stock. Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Raymond James Financial assumed coverage on shares of ADMA Biologics in a report on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 target price for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Mizuho cut their price target on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, Canaccord Genuity Group reduced their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $19.67.

Insider Transactions at ADMA Biologics

In related news, Director Jerrold B. Grossman purchased 12,500 shares of ADMA Biologics stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the transaction, the director owned 513,884 shares in the company, valued at approximately $4,116,210.84. The trade was a 2.49% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 3.90% of the company’s stock.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock opened at $8.95 on Monday. The company has a market cap of $2.07 billion, a P/E ratio of 13.16 and a beta of 0.73. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95. ADMA Biologics Inc has a one year low of $7.21 and a one year high of $20.46. The firm has a fifty day moving average of $8.70 and a two-hundred day moving average of $12.96.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, meeting the consensus estimate of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The business had revenue of $114.49 million for the quarter, compared to the consensus estimate of $139.98 million. During the same quarter in the previous year, the firm earned $0.11 earnings per share. The business’s quarterly revenue was down .3% compared to the same quarter last year. On average, analysts forecast that ADMA Biologics Inc will post 0.82 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.